COX-2 inhibitors - A critical evaluation of side effect data;En kritisk vurdering av bivirkningsdata for COX-2-hemmere

Tidsskrift for den Norske Laegeforening

Volumn 122, Issue 5, 2002, Pages 476-480

  Pomp, E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

CONTROLLED STUDY; DATA ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; UPPER GASTROINTESTINAL TRACT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; PEPTIC ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; OSTEOARTHRITIS; PEPTIC ULCER; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 0037138776     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. COX-2 hemmere
2. Cyklooksygenase-1 og -2 - viktig for klinikere?
3. COX-2 Selectivity and lack of gastrointestinal toxicity: True, true and unrelated?
4. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)- induced gastrointestinal injury?
5. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
6. COX-2-inhibitors
7. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
8. Risk of cardiovascular events associated with selective COX-2 inhibitors
9. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
10. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
11. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
12. Preventing gastrointestinal complications of NSAIDs - Risk factors, recent advances, and latest strategies
13. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane Collaboration metaanalysis of randomized controlled trials
14. COX-2-Selective NSAIDs. New and improved?
15. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
16. SUCCESS-1 in osteoarthritis (OA) trial: Celecoxib significantly reduces risk of upper GI complications compared to NSAIDs while providing similar efficacy in 13,274 randomized patients
17. SUCCESS-1 in osteoarthritis (OA) trial: Celecoxib significantly reduces risk of upper gastrointestinal (UGI) hospitalisations compared to diclofenac and naproxen in 13,274 randomized patients with OA
18. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?
19. Short and long term course of elderly patients with peptic ulcer bleeding - Analysis of factors influencing fatal outcome
20. Outcome studies of drug induced ulcer complications: Do we need them and how should they be done?
21. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
22. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient
23. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis
24. Should the initial drug used to treat osteoarthritis pain be a nonsteroidal anti-inflammatory drug?
25. Medical management of osteoarthritis
26. Additive effect of combined naproxen and paracetamol in rheumatoid arthritis
27. Combining diclofenac with acetaminophen or acetaminophencodeine after oral surgery: A randomized, double-blind single-dose study
28. A comparison of the newer COX-2 drugs and older nonnarcotic oral analgesics
29. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
30. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib
31. Rofecoxib versus placebo ulcer rates
32. In focus - Rofecoxib
33. Celecoxib: Early Australian reporting experience
34. Possible celecoxib-induced gastroduodenal ulceration
35. Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis
36. Gastropathy due to Celecoxib, a cyclooxygenase-2 inhibitor
37. Gastric perforation associated with the use of celecoxib
38. Symptomatic gastric ulcer on Rofecoxib (Vioxx) - Available data on the frequency of symptomatic, serious upper gastrointestinal tract disturbances. From the Bremen register of drug-induced diseases
39. Exacerbation of inflammatory bowel disease associated with use of celecoxib
40. Celecoxib-induced acute pancreatitis and hepatitis: A case report
41. Celecoxib-induced cholestatic hepatitis
42. Acute hepatocellular and cholestatic injury in a patient taking celecoxib
43. Cholestatic hepatitis in association with celecoxib
44. Acute pancreatitis associated with celecoxib
45. Acute drug-induced pancreatitis associated with celecoxib
46. Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis
47. Celecoxib-induced Sweet's syndrome
48. Allergic skin reaction to celecoxib
49. Acute renal failure related to high-dose celecoxib
50. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure
51. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib
52. Acute renal failure associated with rofecoxib
53. Acute onset of auditory hallucinations after initiation of celecoxib therapy
54. Celecoxib- and rofecoxib-induced delirium
55. Visual disturbance associated with celecoxib
56. Anaphylaxis to celecoxib
57. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: A randomized double-blind study